Anti-TNFα therapy for rheumatoid arthritis:: An update

被引:72
作者
Taylor, PC [1 ]
机构
[1] Imperial Coll Sch Sci Technol & Med, Fac Med, Kennedy Inst Div, London W6 8LH, England
关键词
D O I
10.2169/internalmedicine.42.15
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many studies have confirmed that the long term use of biological agents targeting TNFalpha in therapy for rheumatoid arthritis give rise to sustained improvement in symptoms and signs of disease provided the anti-TNF agent is efficacious and of low immunogenicity. The current regimes for infliximab 3 or 10 mg/kg infusion in combination with weekly oral methotrexate, or of subcutaneous etanercept 25 mg twice per week fulfil these criteria. D2E7, a 'human' antibody produced by phage display, has also demonstrated efficacy in clinical trials. It has recently emerged that anti-TNF therapy protects joints from structural damage. One year data for infliximab and methotrexate combination therapy suggest that this regime reduces disability. In early RA, etanercept acts more rapidly than methotrexate to decrease symptoms and retard progression of erosions. In conclusion, for patients with established and early RA, anti-TNF therapies set a new standard for symptom control and joint protection.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 55 条
[1]   A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling [J].
Alexopoulou, L ;
Pasparakis, M ;
Kollias, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (10) :2588-2592
[2]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[3]  
Bhagwat SS, 2001, ARTHRITIS RHEUM, V44, pS213
[4]  
Brennan FM, 1997, BRIT J RHEUMATOL, V36, P643
[5]   Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis [J].
Catrina, AI ;
Lampa, J ;
Ernestam, S ;
af Klint, E ;
Bratt, J ;
Klareskog, L ;
Ulfgren, AK .
RHEUMATOLOGY, 2002, 41 (05) :484-489
[6]  
Charles P, 1999, J IMMUNOL, V163, P1521
[7]  
Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO
[8]  
2-D
[9]  
Christen Urs, 1998, Journal of Interferon and Cytokine Research, V18, pA121
[10]   RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J].
ELLIOTT, MJ ;
MAINI, RN ;
FELDMANN, M ;
KALDEN, JR ;
ANTONI, C ;
SMOLEN, JS ;
LEEB, B ;
BREEDVELD, FC ;
MACFARLANE, JD ;
BIJL, H ;
WOODY, JN .
LANCET, 1994, 344 (8930) :1105-1110